
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of January 2019

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant's name into English)

**Bâtiment Adénine, 60 Avenue Rockefeller
69008 Lyon France**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

ERYTECH Pharma S.A. (the "Company") is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of June 30, 2018 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2018, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
99.1	Unaudited Interim Condensed Consolidated Statements of Financial Position as of December 31, 2017 and June 30, 2018
99.2	Unaudited Interim Condensed Consolidated Statements of Income (Loss) for the Six Months Ended June 30, 2017 and 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ERYTECH Pharma S.A.

Date: January 4, 2019

By: /s/ Eric Soyer

Name Eric Soyer

Title: Chief Financial Officer and Chief Operating Officer

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Amounts in thousands of euros)

	As of	
	June 30, 2018	December 31, 2017
	€	€
ASSETS		
Non-current assets		
Intangible assets	1,629	53
Property, plant and equipment, net	2,759	3,406
Other non-current financial assets	852	234
Total non-current assets	5,241	3,693
Current assets		
Inventories	259	176
Trade and other receivables		76
Other current assets	11,237	5,791
Cash and cash equivalents	165,421	185,525
Total current assets	176,916	191,568
TOTAL ASSETS	182,156	195,261
LIABILITIES AND SHAREHOLDERS' EQUITY		
Shareholders' equity		
Share capital	1,794	1,794
Premiums related to share capital	281,745	281,785
Reserves	(100,567)	(68,346)
Translation reserve	(190)	(203)
Net loss for the period	(18,970)	(33,530)
Total shareholders' equity	163,812	181,419
Non-current liabilities		
Long-term provisions	322	214
Financial liabilities – non-current portion	1,630	2,019
Deferred tax		3
Total non-current liabilities	1,952	2,236
Current liabilities		
Financial liabilities – current portion	796	824
Trade and other payables	12,366	8,076
Other current liabilities	3,231	2,706
Total current liabilities	16,392	11,606
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	182,156	195,261

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(Amounts in thousands of euros, except per share amounts)

	Six Months Ended June 30,	
	2018 €	2017 €
Operating income		
Revenues		
Other income	2,265	1,788
Total operating income	2,265	1,788
Operating expenses		
Research and development	(16,752)	(12,082)
General and administrative	(7,393)	(3,895)
Total operating expenses	(24,145)	(15,977)
Operating loss	(21,880)	(14,189)
Financial income	2,966	160
Financial expenses	(42)	(47)
Financial income	2,924	114
Income tax	(14)	(5)
Net loss	(18,970)	(14,081)
Basic / diluted loss per share (€/share)	(1.06)	(1.42)